Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy.
Carcinogenesis
; 44(12): 795-808, 2023 12 30.
Article
en En
| MEDLINE
| ID: mdl-37796835
ABSTRACT
The inflammasomes play crucial roles in inflammation and cancer development, while the PD-1/PD-L1 pathway is critical for immune suppression in the tumor microenvironment (TME). Recent research indicates a reciprocal regulatory relationship between inflammasomes and PD-1/PD-L1 signaling in cancer development and PD-1 blockade treatment. By activating in diverse cells in tumor tissues, inflammasome upregulates PD-L1 level in the TME. Moreover, the regulation of PD-1/PD-L1 activity by inflammasome activation involves natural killer cells, tumor-associated macrophages and myeloid-derived suppressor cells. Conversely, PD-1 blockade can activate the inflammasome, potentially influencing treatment outcomes. The interplay between inflammasomes and PD-1/PD-L1 has profound and intricate effects on cancer development and treatment. In this review, we discuss the crosstalk between inflammasomes and PD-1/PD-L1 in cancers, exploring their implications for tumorigenesis, metastasis and immune checkpoint inhibitor (ICI) resistance. The combined therapeutic strategies targeting both inflammasomes and checkpoint molecules hold promising potential as treatments for cancer.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Inflamasomas
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Carcinogenesis
Año:
2023
Tipo del documento:
Article